<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>van Oeveren, Wim; Plomgaard, Anne M.; Petersen, Tue H.; Alderliesten, Thomas; Austin, Topun; van Bel, Frank; Benders, Manon; Claris, Olivier; Dempsey, Eugene M.; Franz, Axel; Fumagalli, Monica; Gluud, Christian; Hagmann, Cornelia; Hyttel-Sorensen, Simon; Lemmers, Petra; Pellicer, Adelina; Pichler, Gerhard; Winkel, Per; Greisen, Gorm</td>
</tr>
<tr>
<td><strong>Publication date</strong></td>
<td>2016-01-20</td>
</tr>
<tr>
<td><strong>Type of publication</strong></td>
<td>Article (peer-reviewed)</td>
</tr>
<tr>
<td><strong>Link to publisher's version</strong></td>
<td><a href="http://dx.doi.org/10.1038/pr.2015.266">http://dx.doi.org/10.1038/pr.2015.266</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>© 2016 The Authors. Published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> and <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a></td>
</tr>
<tr>
<td><strong>Item downloaded from</strong></td>
<td><a href="http://hdl.handle.net/10468/4598">http://hdl.handle.net/10468/4598</a></td>
</tr>
</tbody>
</table>
The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury

Anne M. Plomgaard1, Wim van Oeveren2, Tue H. Petersen3, Thomas Alderliesten4, Topun Austin5, Frank van Bel6, Manon Benders4, Olivier Claris6, Eugene Dempsey7, Axel Franz8, Monica Fumagalli9, Christian Gluud10, Cornelia Hagmann11, Simon Hyttel-Sorensen5, Petra Lemmers12, Adelina Pellicer12, Gerhard Pichler13, Per Winkel10 and Gorm Greisen1

BACKGROUND: The SafeBoosC phase II multicentre randomized clinical trial investigated the benefits and harms of monitoring cerebral oxygenation by near-infrared spectroscopy (NIRS) combined with an evidence-based treatment guideline vs. no NIRS data and treatment as usual in the control group during the first 72 h of life. The trial demonstrated a significant reduction in the burden of cerebral hypoxia in the experimental group. We now report the blindly assessed and analyzed treatment effects on electroencephalographic (EEG) outcomes (burst rate and spectral edge frequency 95% (SEF95)) and blood biomarkers of brain injury (S100β, brain fatty acid-binding protein, and neuroketal).

METHODS: One hundred and sixty-six extremely preterm infants were randomized to either experimental or control group. EEG was recorded at 64 h of age and blood samples were collected at 6 and 64 h of age.

RESULTS: One hundred and thirty-three EEGs were evaluated. The two groups did not differ regarding burst rates (experimental 7.2 vs. control 7.7 burst/min) or SEF95 (experimental 18.1 vs. control 18.0 Hz). The two groups did not differ regarding blood S100β, brain fatty acid-binding protein, and neuroketal concentrations at 6 and 64 h (n=123 participants).

CONCLUSION: Treatment guided by NIRS reduced the cerebral burden of hypoxia without affecting EEG or the selected blood biomarkers.

The mortality in extremely preterm infants is approximately 25% and the prevalence of moderate and severe neurodevelopmental impairment in the surviving infants is as high as 25% (1). The etiology behind this neurodevelopmental impairment is multifactorial and partly related to the immaturity of the respiratory and circulatory systems leading to episodes of cerebral hypoxia. Cerebral hypoxia, in turn, through complex interactions between destructive and developmental disturbances may lead to micro- and macroscopic structural brain damage (2). The outcome of relevance to the individual child is neurodevelopmental impairment and possible ensuing disabilities, which cannot be determined before the child is fully grown. Therefore, there is a need for identifying early surrogate outcomes. Long before the age of reliable testing of neurological functions or intelligence, it is possible to visualize brain injuries such as intraventricular and parenchymal hemorrhage by early cranial ultrasound (3). Later cranial ultrasound may show ventricular dilatation as a sign of ex vacuo dilatation caused by cerebral atrophy, or periventricular leukomalacia (2,4,5), whereas magnetic resonance imaging at term equivalent age may show minor degrees of white matter damage (3). Even before structural brain damage is visible, there are other means of detecting injury to the brain of the extremely preterm infant. Several cohort studies have demonstrated good correlations between early electroencephalography (EEG) and later developmental outcomes (6,7). A number of biomarkers show correlation with brain injury. Blood S100β is elevated in newborn infants with intraventricular hemorrhage (8) and hypoxic–ischemic encephalopathy (9). Blood brain fatty acid-binding protein (BFABP) is elevated in elderly patients with neurodegenerative diseases (10) and cerebrospinal fluid neuroketal is elevated in preterm infants with white matter damage on magnetic resonance imaging (11).

The SafeBoosC phase II randomized trial demonstrated that the combination of cerebral oxygenation monitoring by near-infrared spectroscopy (NIRS) combined with an evidence-based treatment guideline (12) vs. blinded collection of cerebral NIRS data and treatment as usual for 72 h significantly reduced the burden of cerebral hypoxia (13). To investigate the

1Department of Neonatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 2HaemoScan B.V., Groningen, The Netherlands; 3Research Unit on Brain Injury Neurorehabilitation Copenhagen, Department of Neurorehabilitation, TBI Unit, Rigshospitalet, Copenhagen University Hospital, Hvidovre, Denmark; 4Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands; 5Rosie Maternity Hospital Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 6Department of Neonatology, Hospital Femme Mere Enfants, Bron, France; 7INFANT Centre, University College Cork, Cork, Ireland; 8Department of Neonatology, University of Tübingen, Tübingen, Germany; 9NICU, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 10Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 11Department of Neonatology, University of Zurich, Zurich, Switzerland; 12Department of Neonatology, La Paz University Hospital, Madrid, Spain; 13Department of Pediatrics, Medical University of Graz, Graz, Austria. Correspondence: Anne Mette Plomgaard (aplomgaard@gmail.com)

Received 17 June 2015; accepted 30 September 2015; advance online publication 20 January 2016. doi:10.1038/pr.2015.266
possible benefits of the experimental intervention on putative surrogate outcomes (14–16), we recorded EEG with amplitude-integrated EEG tracing at the end of the intervention. We also analyzed the blood taken at the beginning and at the end of the intervention for the brain injury molecular biomarkers S100β, BFABP, and neuroketal. We hypothesized that the intervention would reduce the interburst interval (IBI) (6), which was a secondary outcome in the trial. Furthermore, an increased EEG spectral edge frequency 95% (SEF95) (17) and decreased levels of the brain injury molecular biomarkers S100β, BFABP, and neuroketal (exploratory outcomes) were expected.

RESULTS

Infant Characteristics

Patient characteristics at entry were similar across intervention groups but the burden of cerebral hypoxia was significantly lower at the end of intervention (72 h of age) in the experimental group vs. the control group (Table 1). There were no differences in GA and birth weight for infants with and without EEG or with or without molecular biomarkers at the two time points, although more infants without EEG had an Apgar score below five points at 5 min.

Table 1. Entry variables and 72-h outcomes of the included infants

<table>
<thead>
<tr>
<th>At entry variables</th>
<th>Infants with EEG</th>
<th>Infants with blood samples at 6 and 64 h</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Experimental group (n = 68)</td>
<td>Control group (n = 65)</td>
</tr>
<tr>
<td>Birth weight (g), median (range)</td>
<td>821 (410–1,286)</td>
<td>880 (490–1,330)</td>
</tr>
<tr>
<td>GA (wk), median (IQR)</td>
<td>26.6 (25.8–27.4)</td>
<td>27.0 (25.7–27.6)</td>
</tr>
<tr>
<td>Infants below 26 wk of gestation, n (%)</td>
<td>20 (29)</td>
<td>20 (31)</td>
</tr>
<tr>
<td>Twins, n (%)</td>
<td>15 (22)</td>
<td>13 (20)</td>
</tr>
<tr>
<td>Apgar below 5 at 5 min, n (%)</td>
<td>10 (15)</td>
<td>9 (14)</td>
</tr>
<tr>
<td>Antenatal steroids (complete course)</td>
<td>44 (65)</td>
<td>48 (74)</td>
</tr>
</tbody>
</table>

Outcomes at 72 h

| Burden of hypoxia (%hours), median (IQR) | 1.2 (0.4–11.8) | 4 (0.2–29.5) | 1.0 (0.3–6.2) | 1.8 (0.2–21.3) |
| Burden of hypoxia (%hours), median (IQR)* | 16.6 (5.2–65.4) | 52.9 (17.2–152.9) | 16.6 (6.1–63.5) | 63.0 (21.2–174.8) |

IQR, inter quartile range; EEG, electroencephalography.
* P < 0.001 between experimental and control groups (13).

Electroencephalography

Eight infants died before 64 h of age (three in the experimental group and five in the control group) and another eight infants did not have any EEG recordings. Thus, one hundred and fifty EEGs were recorded. Seventeen of the recorded EEGs were not evaluable, which include impossible to read (n = 7), too short (n = 2), no artifact-free epochs (n = 7), or the infant was too old at the time of the EEG recording (n = 1). In total, we therefore analyzed EEGs from 133 infants. Data were collected using eight different EEG monitors: Micromed EEG system (Mogliano, Veneta, Italy) (n = 29); Nervus monitor (Cephalon, Norresundby, Denmark) (n = 29); Olympic cerebral function monitor (Natus, Pleasanton, CA) (n = 29); BRM2 and BRM3 (Natus, former Brainz monitor) (n = 16 and n = 3); NicoletOne video-EEG system (Carefusion, Madison, WI) (n = 16); g.recorder (g.tec, Graz, Austria) (n = 7); and Moberg CNS monitor (Moberg Research, Ambler, PA) (n = 4). The median age at the time of EEG recording, number of sedated infants, and the number of infants treated with opioid did not differ between the intervention groups (Table 2). The interobserver
agreement for the artifact rejection was 92% and the Kappa value was 0.61.

After inverse transformation, the IBIs were normally distributed and by multiplication by 60 s/min expressed as burst rate (bursts/min). Inter cluster correlations (ICCs) were above 0.15 for both burst rate and SEF95. Therefore, the between-groups analyses were conducted after randomly excluding one of each twin pair. Univariate analysis for burst rate and SEF95 was unaffected by GA (P = 0.42 and P = 0.40). The burst rate was significantly affected by EEG filter (P < 0.0001), type of EEG device (P = 0.045), and opioid treatment (P = 0.004). SEF95 was significantly affected by EEG sampling rate (P < 0.0001) and type of EEG device (P<0.0001). Type of EEG device and EEG filter and type of EEG device and EEG sampling rate were strongly correlated; therefore, only EEG filter and EEG sampling rate, opioid treatment, and GA were retained in the multiple regression models. In multiple regression, the mean (SE) burst rate did not differ between the two intervention groups: experimental 7.2 bursts/min (0.72) vs. control 7.7 bursts/min (0.73). The mean SEF95 (SE) did not differ between the intervention groups: experimental 18.1 Hz (0.10) vs. control 18.0 Hz (0.10) (Table 2). The delta-, theta-, alpha-, and beta-power bands did not differ between the intervention groups.

**Blood Biomarkers**

One hundred and twenty-three infants (66 in the experimental group vs. 57 in the control group) had blood samples taken at both the time points (6 and 64 h of age). The concentrations of the three biomarkers in the blood did not differ between the intervention groups neither at 6 nor at 64 h of age (Table 3). The main effect of the intervention is illustrated in Figure 2.

The Randomized Clinical Trial Design

The SafeBoosC phase II trial was a randomized clinical multicentre trial. We blindly evaluated and analyzed EEGs in 84% (133/158) and blood samples in 78% (123/158) of the infants alive at the time of the scheduled EEG recording and blood sampling. To avoid biased regression coefficients (18), we randomly excluded one of each twin pair, if the ICC was above 0.15.

**The Challenges of EEG Recording**

The EEGs were recorded with eight different devices. We therefore used a multiple regression model with corrections for EEG sampling specifications (EEG filter and EEG sampling rate). The difference in SEF95 given the different sampling rates of the EEG devices was not surprising since this was linked to the differences in frequency resolution of the Fast Fourier Transform given the different sampling rates. Some of the EEG

---

**DISCUSSION**

The reduction in the burden of cerebral hypoxia in the group receiving cerebral NIRS monitoring combined with an evidence-based treatment guideline was not reflected in any of the early biomarkers of brain injury that were assessed in the SafeBoosC II trial.
amplifiers used were equipped with a band pass filter from 2 to 15 Hz. This clearly affected the detection of burst rates since the algorithm used for this was based on co-occurrence of slow- and high-frequency oscillations (19). Nevertheless, the burst rates in the SafeBoosC II trial were in line with previously published results in this group of infants (6,20,21) and the IBIs were longer in preterm infants with intraventricular hemorrhage grade III or periventricular hemorrhagic infarctions, which has also previously been observed (22). However, we did not find a correlation between IBI and GA above or below 26 wk; this could be explained by the limited range of GA in the SafeBoosC trial. We therefore believe that the EEG data are robust and the results are reliable. While it is feasible to use EEG as an outcome in a multicentre randomized clinical trial, it should be realized that working with different EEG devices may complicate the analyses by adding heterogeneity.

**The Relevance of the Chosen Biomarkers**

EEG. In term newborn infants, severe hypoxic–ischemic brain injury is associated with EEG burst suppression, lasting hours to days and predicting later neurodevelopmental outcome and death (23,24). EEG burst rate is reduced in preterm infants when arterial $P_{CO_2}$ and blood glucose concentrations are outside the normal range (20). Furthermore in preterm infants, permissive hypercapnia has been associated with increased power in the delta band of the EEG (25). Therefore, we hypothesized that EEG would be a sensitive surrogate marker of any clinically relevant brain effect of the reduction in cerebral hypoxia or hyperoxia that was aimed for in the SafeBoosC II trial. While the effect on cerebral hyperoxia was small and statistically insignificant, the reduction of cerebral hypoxia was highly statistically significant between the intervention groups, as well as potentially clinically relevant—amounting to more than a 50% reduction in cerebral hypoxia (13). We therefore expected the EEG to be different in the intervention groups. Furthermore, our present analyses are not able to determine if IBI or SEF95 is able to predict the long-term cerebral outcome of preterm infants. Several studies have investigated the predictive value of different EEG variables and later neurodevelopmental outcome, although the variables and the timing of the EEG recording that have been used differ (6,7,22), and therefore EEG should not yet be discarded.

### Table 3. Molecular brain injury biomarkers

<table>
<thead>
<tr>
<th>Biomarker (time)</th>
<th>n</th>
<th>Median (pg/ml)</th>
<th>IQR (pg/ml)</th>
<th>Unadjusted analysis</th>
<th>Adjusted analysis with exclusion of one random twin from each twin pair</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>S100Beta (6 h)</strong></td>
<td>E = 75</td>
<td>696</td>
<td>341–983</td>
<td>0.26</td>
<td>0.50&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>C = 68</td>
<td>795</td>
<td>408–1,130</td>
<td>0.51</td>
<td></td>
</tr>
<tr>
<td><strong>S100Beta (64 h)</strong></td>
<td>E = 70</td>
<td>602</td>
<td>267–1,024</td>
<td>0.16</td>
<td>0.10&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>C = 63</td>
<td>601</td>
<td>330–1,074</td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td><strong>BFABP (6 h)</strong></td>
<td>E = 72</td>
<td>176</td>
<td>162–225</td>
<td>0.47</td>
<td>0.10&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>C = 67</td>
<td>193</td>
<td>168–246</td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td><strong>BFABP (64 h)</strong></td>
<td>E = 69</td>
<td>181</td>
<td>155–227</td>
<td>0.47</td>
<td>0.10&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>C = 64</td>
<td>188</td>
<td>158–233</td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td><strong>Neuroketal (6 h)</strong></td>
<td>E = 76</td>
<td>653</td>
<td>461–901</td>
<td>0.14</td>
<td>0.27&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>C = 68</td>
<td>589</td>
<td>329–798</td>
<td>0.14</td>
<td></td>
</tr>
<tr>
<td><strong>Neuroketal (64 h)</strong></td>
<td>E = 69</td>
<td>576</td>
<td>280–856</td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C = 63</td>
<td>602</td>
<td>287–762</td>
<td>0.61</td>
<td></td>
</tr>
</tbody>
</table>

The effect of the intervention at the 6 and 64-h time points in the middle column and the effect on the change over time to the right. E, experimental group; C, control group; IQR, inter quartile range.

<sup>a</sup>Parametric statistics. <sup>b</sup>Nonparametric statistics.

**Figure 2.** Intervention effect on the blood biomarkers illustrated as log ratio for the change in the concentration of the blood biomarkers from 6 to 64 h of age. □ = control group, ■ = experimental group.
as a potential surrogate outcome of randomized clinical trials in preterm infants (14). A systematic review aiming to clarify the predictive value of EEG as a surrogate outcome for the developmental outcome in this group of infants is currently being conducted (26). We could not implement continuous EEG monitoring in this complex, multicentre SafeBoosC II trial and the age of 64 h was chosen as we hypothesized that the end of the intervention was the time with the highest likelihood of detecting an accumulated effect of a reduction of cerebral hypo- or hyperoxia in the experimental group—should such be found. This approach was chosen by extrapolation from term infants with severe hypoxic–ischemic brain injury in whom the EEG effects last some days (27).

We chose burst rate and SEF as the variables for the EEG analyses as these are the most commonly used in preterm infants and have been related to long-term outcomes (6,7,17). Certainly, other more sophisticated analytical methods could be used and may be more sensitive to subtle effects of moderate cerebral hypoxia (28).

**Blood biomarkers.** The three blood biomarkers of brain injury were explorative outcomes of the SafeBoosC II trial and the reduction in the burden of cerebral hypoxia was not reflected in any of them.

*S100β* is the best known of the three brain injury blood biomarkers and is routinely used in the screening of patients with mild to moderate head trauma (29). It is a small calcium-binding protein present in high concentration in Schwann cells and astrocytes (30) and after severe cerebral damage, it leaks from the tissue into the systemic circulation.

A small study in preterm infants found that the level of *S100β* in blood is correlated to the degree of intraventricular hemorrhage (31), whereas a recent larger study showed no correlation (32). The level of *S100β* is increased in term asphyxiated infants and the concentrations have been correlated to the degree of hypoxic–ischemic encephalopathy (9). Whereas hypoxic encephalopathy in term infants typically is the result of a terminal, short and severe hypoxia, the preterm infants in the SafeBoosC II trial were more likely exposed to various grades of cerebral hypoxia for shorter or longer periods during the first 72 h of life. There was no difference in *S100β* between the two intervention groups. This could be because the burden of cerebral hypoxia—even though the reduction in the experimental group was highly significant—was insufficient for the release of the intracellular *S100β* into the systemic circulation. Negative correlations between NIRS levels and *S100β* in critically ill children have been shown previously (33).

BFABP is a small molecule (15 kDa), which is rapidly excreted by the kidneys without cleavage. It is released from astrocytes as response to mechanical damage, ischemia, and oxidative brain damage (34). BFABP has not been investigated previously in extremely preterm infants, but is known to be elevated in patients with various neurodegenerative diseases (10). In adult patients with acute ischemic stroke, BFABP is elevated from 2 to 3 h after the event and remains increased for at least 5 d (34). There was no difference in the level of BFABP between the two intervention groups in the SafeBoosC II trial, which again could be explained by the insufficiency of a moderate global cerebral hypoxic exposure—compared to stroke patients experiencing an acute and severe local cerebral hypoxia.

Neuroketals concentrations in cerebrospinal fluid have been reported to be increased in preterm infants with cerebral white matter damage on magnetic resonance imaging (11). Neuroketals are compounds produced by free radical-induced peroxidation of docosahexaenoic acid, which is solely present in the brain and especially vulnerable to oxidative stress (35). As the burden of hyperoxia was unaffected by the intervention in the SafeBoosC II trial, it may not be surprising that the neuroketal was the same in the two groups.

We did not observe any significant effects of cerebral oxygenation monitoring on blood levels of *S100β*, BFABP, or neuroketal. Our present analyses are not able to decide if these blood biomarkers are predictive of long-term cerebral outcome in this population. Accordingly, we do not yet know if these blood biomarkers are valid surrogate outcomes for cerebral damage in relation to NIRS (14–16).

**Limitations of the Trial**

We did not measure the *P*O₂ in the SafeBoosC II infants, but all other physiological variables were comparable in the two intervention groups (fractional inspired oxygen, peripheral capillary oxygen saturation, mean airway pressure, heart rate, and arterial blood pressure) (13). The incidence of seizures in this population is high, however, the burden of the seizure is low; exceeding 90 s during 24 h of recording on day 3 in only 3% of the infants and thus only amounts to less than 0.2% of recording time (36). In this study, we did not investigate the seizure activity. The blood biomarker and EEG outcomes are unvalidated short-term surrogate outcomes of the intervention and assessment of neurodevelopmental outcome at 2 y of age in this cohort is ongoing. This may enable the validation of these surrogates (14–16).

Our results do not support the hypothesis that the SafeBoosC II NIRS intervention would be effective in reducing brain injury. First, the chosen surrogate outcomes may not be valid. EEG and the blood biomarkers are not established markers for brain injury in preterm infants. However, we examined them as prime candidates and therefore consider the absence of any difference between the groups as an important signal. Is it possible that the reduced burden of cerebral hypoxia was irrelevant for the brain? Although the “burden of cerebral hypoxia”—the accumulated area under the curve expressed in %hours—amounted to more than 200 %hours in some infants, the threshold used as the alarm limit for intervention and for the calculation of the burden was 55% (13). In piglet experiments at term, cerebral oxygenation has to be kept below 30% before severe abnormalities occur in the EEG (37,38) and below 35% for several hours to induce brain injury (39). Furthermore, preterm infants are normally exposed to arterial oxygen saturation of 70% or less in utero, and some neonatal units in the past (1990s) targeted arterial saturation
at low ranges and thereby reduced the risk of retinopathy of prematurity, without increasing the risk of cerebral palsy (40), though it has later been shown that low levels of arterial saturation increase mortality (41). Therefore, our results raise the possibility that cerebral hypoxia at the levels that are common in extremely preterm infants during the first days after birth is really not significant as an etiology for brain (tissue) injury as detectable by EEG and the selected molecular biomarkers at 64 h of age.

Conclusions
Whereas cerebral hypoxia was reduced to less than half in the experimental group, the result was neither reflected in the EEG, nor in the three assessed blood biomarkers.

METHODS

Study Design and Patient Characteristics
The SafeBoosC II randomized clinical trial is a multicentre, blinded, feasibility medical device trial (42). One hundred and sixty-six extremely preterm infants from eight European countries each represented by one NICU were included (1 June 2012–31 December 2013) (13). The infants were randomized to the experimental group (cerebral NIRS monitoring with visible cerebral oxygenation levels combined with evidence-based treatment guideline (12) listing possible interventions if the cerebral oxygenation was out of range: 55–85%) vs. control group (blinded collection of cerebral oxygenation levels combined with treatment as usual). In both intervention groups, the NIRS monitoring was started within 3 h after birth and ended at 72 h of life. The trial is registered at Clinical Trial.gov, NCT01590316; the protocol is available in full at http://www.safeboosc.eu.

The EEG Recording
Recording was specified in a standard operating procedure. At postnatal age of 64 h (±8) at least 120 min of good quality EEG with amplitude-integrated EEG tracing was recorded. Electrodes were placed at P3 and P4 positions according to the international 10–20 system. Needle, disc, or hydrogel electrodes could be used according to local practice and additional electrodes were allowed. The electrode impedance was less than 20 kΩ during the recording. If the child was treated with morphine, other opioids, or sedative medications this was noted in an electronic record form. The raw EEG data were anonymized and uploaded for central analysis via a file transfer protocol.

EEG Analysis
All EEG analysis was performed in Matlab version R2014b (MathWorks, Natick, MA).

Artifact rejection. The raw EEG was band pass filtered (0.5–30 Hz) using a zero-phase filter. Since the amplitude-integrated EEG trace was missing in some infants, the filtered EEG data were converted into range EEG (rEEG) (43) to enable a standardized artifact rejection. The rEEGs were split in 10-min epochs for visual inspection. Artifacts in the rEEG epochs were independently visually identified by two of the authors (GG and AMP) blinded to treatment allocation and the clinical history of the infant. Kappa statistics was used to calculate the level of agreement. For epochs with disagreements, the raw EEG was reviewed and the epoch rejected if the presence of artifacts was confirmed.

Classification of rEEG. The rEEGs were visually classified into four categories: (i) severe burst suppression; (ii) burst suppression (mainly flat lower margin); (iii) discontinuous (lower margin below 25 μV most of the time); or (iii) continuous (lower margin above 25 μV).

IBIs were measured as the time (in seconds) between bursts of nested (high-frequency) oscillations within large slow-wave depolarizations using an extraction algorithm based on the co-occurrence of a slow (0.5–2 Hz) wave and higher (8–22 Hz) frequency oscillation. Consecutive events that occurred within 0.5 s of one another were counted as one and events of duration less than 4/22 of a second were discounted (19). IBIs were calculated for each of the artifact-free 10-min epochs and expressed as the median of all IBIs in all included epochs.

Spectral analysis. For each artifact-free 10-min epoch spectral analyses were conducted using Matlab routines (Neurospec 2.0, Neurospec.org). The EEG data were segmented into epochs of 2 s with an overlap of 50% (1s). After Fast Fourier Transformation, the spectrum was subdivided into frequency bands: delta (0.5–4 Hz), theta (4.5–8 Hz), alpha (8.5–13 Hz), and beta (13.5–30 Hz). The spectral distribution was calculated as the square root of the power in each band and expressed as percentages adding up to 100%. A grand mean of the spectral distribution for each infant was calculated as the mean of all epochs.

SEF95 for each infant was defined as the frequency between 0.5 and 30 Hz, below which 95% of the power was present. SEF95 is expressed as a mean of all epochs.

Brain Injury Biomarkers in Blood
Blood sampling, plasma storage and analyses were specified in a standard operating procedure. At the age of 6 h (+1) and 64 h (+1), 1 ml of blood was collected. A blood sample was only taken if the infant had an indwelling arterial or venous line. The blood was sampled in heparinized tubes and centrifuged (1200×g for 12 min) before the plasma was transferred to a small screw-cap tube. The samples were kept at −40 to −20°C for a maximum of 1 wk, thereafter at −80°C (±1°C) for prolonged storage. After inclusion of the last patient, the samples were sent on dry ice to a central laboratory (HaemoScan, Groningen, The Netherlands).

Laboratory Analysis
The blood samples were analyzed for the three different brain injury biomarkers. The laboratory technician was unaware of the medical history and allocation of the infant. S100β (50 μl) was assessed by ELISA. Clone I82 monoclonal antibody was used as capture antibody (Abnova, Taipei, Taiwan) and biotinylated clone 8B10 as detection antibody (Hytest, Turku, Finland). Intra-assay variance is 4.6% and the lower level of quantification (LLOQ) is 39 pg/ml. BEABP (50 μl) was determined by means of ELISA with BFABP polyclonal capture antibodies and monoclonal detection antibody (HaemoScan). Intra-assay variance is 6.4% and the lower level of quantification is 150 pg/ml. Neuroketol (60 μl) determination was performed by competitive enzyme immunoassay based on purified rabbit antibodies against KLH complexed neuroketol (HaemoScan). Intra-assay variance is 10% and the lower level of quantification is 4.1 pg/ml.

Ethics
The SafeBoosC phase II trial was approved by each hospital’s research ethics committee (Hospital Femme Mere Enfants, Lyon, France; Rigshospitalet, Copenhagen, Denmark; La Paz University Hospital, Madrid, Spain; Cork University Maternity Hospital, Cork, Ireland; Wilhelmina Children’s Hospital, Utrecht, The Netherlands; Medical University of Graz, Graz, Austria; Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy; and Rosie Hospital, Cambridge University Hospitals, United Kingdom), and where required (Austria, Denmark, and France) by the competent authority responsible for medical devices. Written informed parental consent was mandatory before inclusion in the trial.

STATISTICS

Between-Groups Analysis
EEG: The distribution of the IBIs and SEF95 were tested for normality, if not normal, the data were transformed. For the EEG outcomes, a general univariate regression model of each EEG quantity on GA (above or below 26 wk) and on each of the indicators of opioid treatment, of treatment with sedative, of EEG filter, of EEG sampling rate, and of type of EEG device was conducted to see which of these quantities had a significant (P < 0.05) effect on the EEG outcome. The variables with significant effect on the EEG outcomes were included in multiple regression models, thereafter the estimated mean (SE) was calculated and comparisons between the two groups were conducted.
Molecular biomarkers. If the molecular biomarkers were not normally distributed, logarithmic transformation was attempted. For data with normal distribution before or after transformation a linear mixed-model analysis using time, intervention (experimental or control), and the interaction between time and intervention was conducted. An unstructured covariance matrix was used. The analyses were adjusted by GA (above or below 26 wk) and centre. If the data did not follow a normal distribution, the Mann–Whitney test was used. For all analyses the two-sided $P$ values with a threshold of 0.05 were used.

Inter Cluster Correlation
The outcomes of EEG (IBI and SEF95) and the biomarker concentrations were tested for ICC to determine the correlation between the infants in each pair of twins. A mixed-model analysis was carried out for each of the EEG and biomarker outcomes: using birth (twin pair) as a random intercept. If ICC was less than 0.15, then all infants were included in the analysis for that outcome. If the ICC was higher than 0.15, one twin from each cluster was removed at random (using a web-based randomization program (RANDOM.ORG, Dublin, Ireland)) and the between-groups analyses were conducted on the remaining infants.

Other Analyses
The interobserver agreement for the artifact rejection of the rEEGs was estimated as proportion and the Kappa value was estimated. The analyses were conducted using IBM SPSS Statistics for Windows version 20.0.0, (IBM SPSS, Armonk, NY) and SAS version 9.3, (SAS Institute, Cary, NC).

ACKNOWLEDGMENT
The authors would like to acknowledge Caroline Hartley for willingly sharing the Matlab script for the inter-event intervals.

STATEMENT OF FINANCIAL SUPPORT
The Danish Council for Strategic Research financially supported this work through an unconditional and unrestricted grant of DKK 11,100,105. The funder had no role in the design, conduct, or analysis of the trial.

Disclosure: None of the authors have any conflicts of interest to disclose.

REFERENCES
SafeBoosC II: molecular and EEG outcomes


42. Hyttel-Sorensen S, Austin T, van Bel F, et al. A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): study protocol for a randomized controlled trial. Trials 2013;14:120.